Claudia Ledda

Claudia Ledda

Auto-generated profile, based on publicly available information

Claudia Ledda

Department of Neuroscience “Rita Levi Montalcini” University of Turin Turin Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Open access
PDF file
MAMicol Avenali
Micol Avenali
RZRoberta Zangaglia
Roberta Zangaglia
GCGiada Cuconato
Giada Cuconato
IPIlaria Palmieri
Ilaria Palmieri
AAAlberto Albanese
Alberto Albanese
EVEnza Maria Valente
Enza Maria Valente
Background: GBAvariants increase the risk of developing Parkinson disease (PD) and influence its outcome. Deep brain stimulation (DBS) is a recognised therapeutic option for advanced PD. Data on DBS long-term outcome inGBAcarriers are scarce.Objective: To elucidate the impact ofGBAvariants on long-term DBS outcome in a large Italian cohort.Methods: We retrospectively recruited a multicentric Italian DBS-PD cohort and assessed: (1)GBAprevalence; (2) pre-DBS clinical features; and (3) outcomes of motor, cognitive and other non-motor features up to 5 years post-DBS.Results: We included 365 patients with PD, of whom 73 (20%) carriedGBAvariants. 5-year follow-up data were available for 173 PD, including 32 mutated subjects. GBA-PD had an earlier onset and were younger at DBS than non-GBA-PD. They also had shorter disease duration, higher occurrence of dyskinesias and orthostatic hypotension symptoms.At post-DBS, both groups showed marked motor improvement, a significant reduction of fluctuations, dyskinesias and impulsive-compulsive disorders (ICD) and low occurrence of most complications. Only cognitive scores worsened significantly faster in GBA-PD after 3 years. Overt dementia was diagnosed in 11% non-GBA-PD and 25% GBA-PD at 5-year follow-up.Conclusions: Evaluation of long-term impact ofGBAvariants in a large Italian DBS-PD cohort supported the role of DBS surgery as a valid therapeutic strategy in GBA-PD, with long-term benefit on motor performance and ICD. Despite the selective worsening of cognitive scores since 3 years post-DBS, the majority of GBA-PD had not developed dementia at 5-year follow-up.

12 October 2022 in European Journal of Neurology
Verified
Journal Article
Open access
GIGabriele Imbalzano
Gabriele Imbalzano
DRDomiziana Rinaldi
Domiziana Rinaldi
GCGiovanna Calandra‐Buonaura
Giovanna Calandra‐Buonaura
MCManuela Contin
Manuela Contin
FAFederica Amato
Federica Amato
Carlo Alberto ArtusiCarlo Alberto Artusi
Carlo Alberto Artusi
Background and purpose: Treatment of freezing of gait (FoG) and other Parkinson disease (PD) axial symptoms is challenging. Systematic assessments of axial symptoms at progressively increasing levodopa doses are lacking. We sought to analyze the resistance to high levodopa doses of FoG, posture, speech, and altered gait features presenting in daily‐ON therapeutic condition.Methods: We performed a pre‐/postinterventional study including patients treated with levodopa/carbidopa intestinal gel infusion (LCIG) with disabling FoG in daily‐ON condition. Patients were evaluated at their usual LCIG infusion rate (T1), and 1 h after 1.5× (T2) and 2× (T3) increase of the LCIG infusion rate by quantitative outcome measures. The number of FoG episodes (primary outcome), posture, speech, and gait features were objectively quantified during a standardized test by a blinded rater. Changes in motor symptoms, dyskinesia, and plasma levodopa concentrations were also analyzed.Results: We evaluated 16 patients with a mean age of 69 ± 9.4 years and treated with LCIG for a mean of 2.2 ± 2.1 years. FoG improved in 83.3% of patients by increasing the levodopa doses. The number of FoG episodes significantly decreased (mean = 2.3 at T1, 1.7 at T2, 1.2 at T3; p = 0.013). Posture and speech features did not show significant changes, whereas stride length (p = 0.049), turn duration (p = 0.001), and turn velocity (p = 0.024) significantly improved on doubling the levodopa infusion rate.Conclusions: In a short‐term evaluation, the increase of LCIG dose can improve "dopa‐resistant" FoG and gait issues in most advanced PD patients with overall good control of motor symptoms in the absence of clinically significant dyskinesia.

11 November 2025 in Neurology
Verified
Journal Article
Open access
MAMicol Avenali
Micol Avenali
Carlo Alberto ArtusiCarlo Alberto Artusi
Carlo Alberto Artusi
RCRoberto Cilia
Roberto Cilia
GGGiulia Giannini
Giulia Giannini
GCGiada Cuconato
Giada Cuconato
EVEnza Maria Valente
Enza Maria Valente
Deep brain stimulation (DBS) is an established treatment for Parkinson disease (PD). In patients carrying GBA1 variants (GBA-PD), concerns persist that DBS may accelerate cognitive decline. This study investigated the potential additive effects of GBA1 genotype and DBS on long-term motor and nonmotor outcomes. This multicenter retrospective, controlled, Italian study included 3 groups: DBS-treated PD patients either carrying or noncarrying GBA1 variants (DBS-nonGBA-PD and DBS-GBA-PD) and GBA-PD patients who fulfilled DBS criteria but eventually were not operated. As secondary aims, we assessed the clinical outcomes of DBS-GBA-PD stratified by GBA1 variant classes and by different DBS targets. Cognitive, motor, and other nonmotor features were collected at baseline and after 1, 3 and, when available, 5 years. Between-group comparisons used χ2 and Kruskal-Wallis tests with Bonferroni correction. Longitudinal changes were analyzed with linear mixed-effects models. Subgroup analyses were performed by GBA1 variant class and DBS target. A total of 615 participants were included: 430 DBS-nonGBA-PD (age 57.4 ± 7.7 years, 32% female), 109 DBS-GBA-PD (age 53.5 ± 8.4 years, 38% female), and 76 nonDBS-GBA-PD (age 57.7 ± 8.1 years, 37% female). At baseline, groups were largely matched for clinical features. Longitudinally, both DBS groups showed marked motor improvement (dyskinesias, on-off phenomenon, and wearing-off, all p vs T0 < 0.001), a benefit which was absent in nonDBS-GBA-PD. At 5 years, dementia occurred more frequently in DBS-GBA-PD and nonDBS-GBA-PD compared with DBS-nonGBA-PD (25.5% vs 36.8% vs 10.8%, p < 0.001). Hallucinations and urinary problems increased in both GBA-PD groups than nonGBA-PD (p-between <0.001 and 0.02, respectively), regardless of DBS. No relevant differences emerged on stratification for variant classes or DBS targets, up to 3 years postsurgery. Despite its retrospective design, this study supports DBS as a valid therapeutic option for GBA-PD, providing prolonged benefits on motor symptoms and quality of life. The accelerated cognitive decline observed in GBA-PD, compared with non-mutated participants, was similarly present in both operated and non-operated groups, suggesting it is driven by the genotype rather than DBS itself. This study provides Class III evidence that DBS does not worsen cognitive function in patients with GBA1-associated PD.

1 December 2024 in Journal of Parkinson’s Disease
Verified
Journal Article
Open access
Carlo Alberto ArtusiCarlo Alberto Artusi
Carlo Alberto Artusi
CLClaudia Ledda
Claudia Ledda
SGSilvia Gallo
Silvia Gallo
DRDomiziana Rinaldi
Domiziana Rinaldi
CCCorrado Campisi
Corrado Campisi
MFMargherita Fabbri
Margherita Fabbri
Background: Freezing of gait (FoG) is a debilitating symptom of Parkinson's disease (PD) with limited response to dopaminergic medication and subthalamic deep brain stimulation (STN-DBS). Substantia nigra pars reticulata (SNr) stimulation could improve FoG. Objective: To analyze the effect of combined STN-SNr stimulation at different frequencies on FoG. Methods: We performed a double-blind, cross-over, randomized pilot trial involving STN-DBS treated PD patients with FoG. Participants received: high-frequency (HF) STN-DBS (S), combined HF-STN and SNr stimulation (C1), and combined HF-STN and low-frequency (LF) SNr stimulation (C2), for one month each. The primary endpoint was the score change in the New-Freezing-of-Gait-Questionnaire (NFOG-Q). Secondary analyses were performed on motor complications, axial symptoms, daily living activities, psychiatric symptoms, sleep, and patient preference. Results: Fifteen patients received at least one combined stimulation. No significant difference in NFOG-Q scores was found between S, C1, and C2; one-third of patients showed a clinically significant improvement (≥8 points) with combined stimulations. Motor complications improved significantly with C1 and C2 (C1-S: 3.6 ± 3.8 vs. 4.9 ± 3.8, p = 0.046; C2-S: 2.7 ± 3.1 vs. 4.9 ± 3.8, p = 0.005). 80% of patients preferred the combined STN-SNr stimulation while blinded. All adverse events were manageable. Conclusions: Our study did not prove a statistically significant improvement in NFOG-Q with STN-SNr stimulation; however, one-third of patients experienced a clinically meaningful FoG improvement, and the majority preferred to maintain STN-SNr stimulation. STN-SNr stimulation was both safe and effective in addressing motor complications and improving sleep quality, highlighting the importance of further exploration into the effects of combined STN-SNr stimulation.

23 July 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
CLClaudia Ledda
Claudia Ledda
GIGabriele Imbalzano
Gabriele Imbalzano
MTMarta Maria Tangari
Marta Maria Tangari
ACAnna Covolo
Anna Covolo
FDFrancesca Donetto
Francesca Donetto
ARAlberto Romagnolo
Alberto Romagnolo

28 June 2024 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
MFMargherita Fabbri
Margherita Fabbri
CLClaudia Ledda
Claudia Ledda
TSTommaso Schirinzi
Tommaso Schirinzi
Carlo Alberto ArtusiCarlo Alberto Artusi
Carlo Alberto Artusi
AAAnna Rosa Avallone
Anna Rosa Avallone
EPEleonora Del Prete
Eleonora Del Prete
Background: In spite of being considered the gold-standard of care, little is known about the real-life use of inhome and multidisciplinary care in atypical parkinsonism. Objective: Primary: Examine real-life multidisciplinary care use for Progressive Supranuclear Palsy (PSP). Secondary: a) Compare PSP care to advanced Parkinson's disease (APD) care; (b) Explore demographic and clinical variables associated with care needs in both groups. Methods: A cross-sectional multicenter observational study enrolled 129 PSP patients and 65 APD patients (Hoehn and Yahr >= 3), matched for sex and age. Univariate and multivariate regression analysis were performed. Results: Over the previous year, 40 % of PSP patients did not encounter a physical therapist, while only one-third met a speech and language therapist and 5 % an occupational therapist. More than 20 % received in-home care and 32 % needed home structural changes. Compared to APD, PSP patients required more day-time, night-time and home structural changes. When considering both PSP and APD in multivariate analysis, reduced functional autonomy and living without a family caregiver were both related to day-time home assistance and to the need of at least one home care service. A PSP diagnosis compared to APD was a risk factor for having at least four multidisciplinary visits in a year. Finally, PSP diagnosis and being from the Northern Italy were significantly related with home structural changes. Conclusions: There's a significant gap in providing multidisciplinary care for PSP patients. Our findings emphasize the need for a shared, integrated care plan at a national level for patients with atypical parkinsonism.